Subsequent Events	9 Months Ended
Sep. 30, 2014
Subsequent Events [Abstract]
Subsequent Events [Text Block]	18. Subsequent Events Multi Channel Systems MCS GmbH On October 1, 2014, the Company, through its wholly-owned Biochrom Limited subsidiary, acquired all of the issued and outstanding shares of Multi Channel Systems MCS GmbH (“MCS”), which has its principal offices in Germany, for approximately $9.5 million. The Company funded the acquisition from its existing cash balances. MCS is a developer, manufacturer and marketer of in vitro and in vivo electrophysiology instrumentation for extracellular recording and stimulation. This acquisition is complementary to the in vitro electrophysiology line currently offered by the Company’s wholly-owned Warner Instruments subsidiary. The Company is in the process of determining the fair value of the various tangible and intangible assets acquired as a result of this acquisition. The Company considers this acquisition immaterial for the purposes of proforma financial statement disclosures. Triangle BioSystems, Inc. On October 1, 2014, the Company acquired all of the issued and outstanding shares of Triangle BioSystems, Inc. (“TBSI”), which has its principal offices in North Carolina, for approximately $1.6 million, net of cash acquired. The Company funded the acquisition from borrowings under its credit facility. See Note 14 for a further description of such credit facility. TBSI is a developer, manufacturer and marketer of wireless neural interface equipment to aid in vivo neuroscience research, especially in the fields of electrophysiology, psychology, neurology and pharmacology. This acquisition is complementary to the behavioral neuroscience lines currently offered by the Company’s wholly-owned Panlab and Coulbourn subsidiaries. The Company is in the process of determining the fair value of the various tangible and intangible assets acquired as a result of this acquisition. The Company considers this acquisition immaterial for the purposes of proforma financial statement disclosures.

18. Subsequent Events

Multi Channel Systems MCS GmbH

On October 1, 2014, the Company, through its wholly-owned Biochrom Limited subsidiary, acquired all of the issued and outstanding shares of Multi Channel Systems MCS GmbH (“MCS”), which has its principal offices in Germany, for approximately $9.5 million. The Company funded the acquisition from its existing cash balances.

MCS is a developer, manufacturer and marketer of in vitro and in vivo electrophysiology instrumentation for extracellular recording and stimulation. This acquisition is complementary to the in vitro electrophysiology line currently offered by the Company’s wholly-owned Warner Instruments subsidiary.

The Company is in the process of determining the fair value of the various tangible and intangible assets acquired as a result of this acquisition.

The Company considers this acquisition immaterial for the purposes of proforma financial statement disclosures.

Triangle BioSystems, Inc.

On October 1, 2014, the Company acquired all of the issued and outstanding shares of Triangle BioSystems, Inc. (“TBSI”), which has its principal offices in North Carolina, for approximately $1.6 million, net of cash acquired. The Company funded the acquisition from borrowings under its credit facility. See Note 14 for a further description of such credit facility.

TBSI is a developer, manufacturer and marketer of wireless neural interface equipment to aid in vivo neuroscience research, especially in the fields of electrophysiology, psychology, neurology and pharmacology. This acquisition is complementary to the behavioral neuroscience lines currently offered by the Company’s wholly-owned Panlab and Coulbourn subsidiaries.

The Company is in the process of determining the fair value of the various tangible and intangible assets acquired as a result of this acquisition.

The Company considers this acquisition immaterial for the purposes of proforma financial statement disclosures.